Latest Breaking News On - Actalycabtagene autoleucel - Page 1 : comparemela.com

​​CAR-T cell therapies, dubbed ‘living drugs,’ involve extracting a patient’s T-cells, genetically modifying them to express Chimeric Antigen Receptors (CARs), specifically designed to recognise cancer cells and infusing them back into the patient.

Dinesh madhavanAditya muraliApollo hospitals enterprisesGroup oncologyApollo cancer centresAntigen receptorsSenior consultantNeema bhatApollo hospitals enterprises limitedPaediatric oncologyHaemato oncologyChimeric antigen receptorsActalycabtagene autoleucel